1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.

Slides:



Advertisements
Similar presentations
Quality of life in relation to costs
Advertisements

QALY: veel bekritiseerd, maar nooit meer dan het alternatief”
Quality of life (Utility) Measurements In Relation to Health Economics
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
Justice and Economic Evaluation Prof. Dr. Jan Busschbach
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 The QALYs debate  Prof. dr. Jan J.V. Busschbach, Ph.D.  Erasmus MC  Institute for Medical Psychology and Psychotherapy.
1 Does it make a difference for the patient? Survival & Quality of life  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and.
You have 10 seconds to name… Concepts of Health.
1 A Health Economic View on Borderline Personality Disorder Prof. dr. Jan Busschbach Viersprong Institute for studies on Personality Disorders Medical.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Prof. dr. Jan van Busschbach Department of Medical Psychology & Psychotherapy Erasmus MC.
Utility Assessment HINF Medical Methodologies Session 4.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
COST–EFFECTIVENESS ANALYSIS AND COST-UTILITY ANALYSIS
QALYs and Ethics Prof. dr. Jan van Busschbach 11.
Quality of life Assessment introduction
QUALITY OF LIFE ASSESSMENT IN PEOPLE LIVING WITH HIV/AIDS Antonieta Medina Lara HIV/AIDS and STI Knowledge Programme Liverpool School of Tropical Medicine.
Quality of Life Assessment in Clinical Trials Adapted from Introduction to Clinical Trials Biostatistics.
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
INTRODUCTION TO HEALTH ECONOMICS March 2007 Health Economic Course Series: 1 of 12
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
QALYs and Ethics Is there an ethical / valid alternative?
1 Health Economics  Comparing different allocations  Should we spent our money on Wheel chairs Screening for cancer  Comparing costs  Comparing outcome.
Overview of the EQ-5D Purpose and origins of the descriptive system.
Definitions: Health, Disability, Quality of Life These are abstract concepts, so there is no single and permanent way to define, and hence to measure,
GLOSSARY. DIMENSIONS OF HEALTH PHYSICAL HEALTH - Relates to the efficient functioning of the body and its systems, and includes the physical capacity.
Why use the EQ-5D? What are the alternatives?. What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to.
1 Reconciliation of Economic Arguments and Clinical Practice Monday November 4, 2002 ISPOR, Rotterdam Jan Busschbach PhD, –Department of Medical Psychology.
Measuring Health Status
1 QALY, Burden of Disease and Budget Impact  Jan J.V. Busschbach, Ph.D.  Erasmus MC, Rotterdam, The Netherlands  
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
The International Classification of Functioning, Disability and Health (ICF) Section 1 Els R. Nieuwenhuijsen, PhD, MPH, OTR.
Cost-effectiveness of psychotherapy for personality disorders Djøra Soeteman Viersprong Institute for Studies on Personality Disorders Erasmus Medical.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
CIA Annual Meeting Session 3203 Measuring Wellness: The Issues? Tom Brogan President June 28 th, 2005.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Cost effectiveness as argument for reimbursement in prevention Jan J. v. Busschbach, Ph.D. Erasmus MC –Institute for Medical Psychology and Psychotherapy.
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
Economic evaluation of psychotherapy for personality disorders: burden of disease and cost-effectiveness Djøra Soeteman Viersprong Institute for Studies.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
11 Cost Effectiveness in Preventing Crime  Jan van Busschbach, Djøra Soeteman  Viersprong Institute for studies on Personality Disorders VISPD  Erasmus.
1 The Cost Effectiveness of Treatment of Personality Disorder  Dr. Jan J.V. Busschbach  PTC De Viersprong, Erasmus MC, Rotterdam, 
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Cost Effectiveness  Jan J.V. Busschbach, Ph.D.  Viersprong Institute for studies on Personality Disorders VISPD  Erasmus.
Introduction to decision analysis Jouni Tuomisto THL.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
Statistical Issues in the Analysis of Patient Outcomes April 11, 2003 Elizabeth Garrett Oncology Biostatistics Acknowledgement: Thanks to Ron Brookmeyer.
1 The Economics of Health Care and New Technologies Friday October 18, 2002 Between Technology and Humanity, Brussels Jan Busschbach PhD, –Department of.
Introduction to decision analysis Jouni Tuomisto THL.
1 Value of Information in relation to risk management  Prof. Dr. Jan J.V. Busschbach.
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Cost-Effectiveness of Psychotherapy (for Personality Disorders) Prof. dr. Jan van Busschbach.
Health Economic Course Series
Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR.
How to weight cost effectiveness in appraisal NVTAG / CVZ course: The appraisal process, work in progress 22th of April 2009 Jan van Busschbach.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
1 VAS, SG, TTO and PTO An Interactive Introduction.
1 Utilization of Quality of Life Research in Decision-Making and Policy  Prof. Dr. Jan J.V. Busschbach  Erasmus MC, Rotterdam, The Netherlands  Section.
Global burden of diseases
Quality of Life Assessment
Prof. Dr. Jan J.V. Busschbach
Measurement Wu Gong, MS, MD
Justification treatment cost
PUBLIC HEALTH – INTRODUCTION HEALTH STATUS OF A POPULATION
Presentation transcript:

1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong Institute for studies on Personality Disorders

I want to live in… Land A  Life expectancy 80  Quality of life 0.8  Cures common diseases Land B  Life expectancy 78.8  Quality of life 0.75  Cures catastrophic diseases 2

I would spend money on…  High incidence  Many patients  High burden  Genetic cause  Effective treatment  Curtain outcome  Low incidence  Limited patients  Low burden  Behavioral cause  Non effective treatment  Uncertain outcome 3

I would spend money on…  Low incidence  Many patients  High burden  Genetic cause  Effective treatment  Curtain outcome  High incidence  Limited patients  Low burden  Behavioral cause  Non effective treatment  Uncertain outcome 4

5 New cancer therapy SymptomsDrug XDrug Y Survival days Days sick of chemotherapy Days sick of disease TWiST

6 Time Without Symptoms of disease and subjective Toxic effects of treatment: TWiST  Richard Gelber  statistician  Count …  Days not sick from treatment  Days not sick from disease 6

7

8 Fit new therapy in fixed budget  50 patients each year (per hospital)  Drug x: 50 x euro = euro  Drug y: 50 x euro = euro  Drug budget for x or y = euro  Number of patient Drug x: euro / = 28.5 patients Drug y: euro / = 25.0 patients  Survival in days Drug x: 28.5 patients x 300 days = days Drug y: 25.0 patients x 400 days = days  Survival in TWiST Drug x: 28.5 patients x 190 TWiST = days Drug y: 25.0 patients x 220 TWiST = days

9 TWiST: ignores differences in quality of life  TWiST  Healthy = 1  Sick (dead) = 0  Q-TWiST Quality of life adjusted TWiST  Make intermediate values 1.0; 0.75; 0.50; 0.25; 0.00  How to scale quality of life? Quality of life 1.0

10 Uni-dimensional scale  Quality of life  World Health Organization, 1947  “…. Health is physical, mental and social well-being and not merely the absence of disease or infirmity...”  But we need a uni-dimensional scale  Like temperature  IQ  Depression scale  School grad  So we need a overall judgment…

Generic QoL Questions (SF-36) 11

Complex interpretation 12

Weighted index 13

14 Visual Analogue Scale  Does the scale fit Q-TWIST?  Is 2 days 0.5 Q = 1 day 1.0 Q ? 14 Dead Normal health X ?=?=

Interval / Ratio scale  Ratio or interval scale  Difference 0.00 and 0.80 must be 8 time higher than 0.10  Uncommon in psychology 15

16 Time Trade-Off  Wheelchair  With a life expectancy: 50 years  How many years would you trade-off for a cure?  Max. trade-off: 10 years  QALY(wheel) = QALY(healthy)  Y * V(wheel) = Y * V(healthy)  50 V(wheel) = 40 * 1.00  V(wheel) =

17  Example  Blindness  Time trade-off value is 0.5  Life span = 80 years  0.5 x 80 = 40 QALYs Quality Adjusted Life Years (QALY) X Life years x 80 = 40 QALYs

18 QALY  Count life years  Value (V) quality of life (Q)  V(Q) = [0..1] 1 = Healthy 0 = Dead  One dimension  Adjusted life years (Y) for value quality of life  QALY = Y * V(Q) Y: numbers of life years Q: health state V(Q): the value of health state Q  Also called “utility analysis”

19 Q-TWiST = QALY  Several initiatives early seventies  Epidemiologist and health economists  Part of QALY concept  Quality Adjusted Life Years  QALY = Q-TWiST 19

20 Area under the curve

21  A new wheelchair for elderly (iBOT)  Special post natal care Which health care program is the most cost-effective?

SegwayDean Kamen

23  A new wheelchair for elderly (iBOT)  Increases quality of life = 0.1  10 years benefit  Extra costs: $ 3,000 per life year  QALY = Y x V(Q) = 10 x 0.1 = 1 QALY  Costs are 10 x $3,000 = $30,000  Cost/QALY = 30,000/QALY  Special post natal care  Quality of life = 0.8  35 year  Costs are $250,000  QALY = 35 x 0.8 = 28 QALY  Cost/QALY = 8,929/QALY Which health care program is the most cost-effective?

24 QALY league table

Citations in PubMed

Orphan drugs  Pompe disease  Classical form: infants € /QALY; adults €  New estimates: /QALY;  Low cost effectiveness but…  High burden  Low prevalence  Little own influence on disease  High consensus in the field Coalition patient, industry, doctors and media Low perceived incertainty 26

 …it must be that QALYs are invalid We don’t like the results…

In the past, much criticism Cohen CB. Quality of life and the analogy with the Nazis. Journal of Medicine and Philosophy 8: , 1983.

Criticism remains 29 ….the strictly fascist essence of those QALYs (so-called Quality-Adjusted Life Years)…

30 Chris Murray  WHO avoided QALY  (read: disliked QALYs)  (read disliked health economics)  But WHO in need of a measure of health…  Asked Havard…  “Anything… but QALY”  Chris Murray  School of Public Health  Worked outside  Health economics  Med Decision Making  DALY

31 Burden of disease: QALY lost = DALY (Disability adjusted life year) DALY QALY

ABC Health Egalitarian Concerns: Burden of disease

ABC Levensjaen Costs/QALY as indicator of solidarity € € €

34 Burden as criteria Pronk & Bonsel, Eur J Health Econom 2004, 5:

35 Costs/QALY versus Burden of disease 35 € € € € € 0 Burden of disease X X X X X

36 Dutch Council for Public Health and Health Care (RvZ, 2006) 36

37 QALY debate  Fairness is the issue in the QALY debate  QALY measurement is the straw man  Complex metric discussion  Most debate about quality of life assessment  QALY are seen as unfair  But: QALYs are needed to operationalise fairness 37

38 Conclusion  Quality of life can be measured  Usual multidimensional  Unidimensional: QALYs  QALYs can validly be use in cost effectiveness research  Burden of disease is also a criterion  On need QALYs to measure burden